Vor Biopharma (NASDAQ:VOR) Upgraded at Zacks Research

Zacks Research upgraded shares of Vor Biopharma (NASDAQ:VOR) from a strong sell rating to a hold rating in a research note released on Wednesday morning,Zacks.com reports.

Other research analysts have also issued research reports about the company. Wall Street Zen lowered Vor Biopharma to a “strong sell” rating in a report on Saturday, June 28th. HC Wainwright raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Monday, June 30th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Vor Biopharma currently has an average rating of “Buy”.

Vor Biopharma Price Performance

Vor Biopharma stock opened at $1.74 on Wednesday. Vor Biopharma has a 12 month low of $0.13 and a 12 month high of $3.29. The business’s 50 day moving average is $2.12. The stock has a market capitalization of $220.42 million, a PE ratio of -0.13 and a beta of 2.05.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($2.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($1.61).

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.